Avaliação da expressão da proteína BRAFV600E em carcinomas papilíferos de tireoide

Abstract

Introduction: Papillary thyroid carcinoma (TLC) is the most common histological subtype of all the neoplasms of this gland. It has an indolent evolution in most cases, however, some still have a poor prognosis, according to their characteristics. pathological conditions. Among them, BRAFV600E protein expression is under study, due to the its possible value in the prognosis of patients. Objectives: To evaluate the immunohistochemical expression of BRAFV600E protein in TLC and to correlate with clinical pathological characteristics. Materials and Methods: We selected cases of CPT ≥1cm from patients who had thyroidectomy samples in the pathology laboratory biobank. These were BRAFV600E protein expression by immunohistochemical method and regarding its clinical and pathological characteristics. The variables described and related to BRAFV600E protein expression were age, sex, laterality, size, multifocality, extrathyroid extension, lymph node metastases and lymphovascular invasion. Intensity and percentage of cells with expression were also analyzed. Results: A BRAFV600E mutation prevalence was detected in 26 (66.7%) of the 39 cases. moderate intensity (12/26, 46%) and expression in <50% of tumor cells (18/26, 70%). There was no association between protein expression and pathological clinical characteristics of TLC. The intensity and percentage of mutated cells also did not have statistical significance. Conclusion: It was found a high prevalence of the expression of BRAFV600E protein in CPT, however, in the present study, its positivity was not associated with the clinical-pathological characteristics that predict tumor aggressiveness, It can be stated that it has prognostic value.